Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

NCT07579845 — Not applicable, Recruiting, 60 participants, OvationLab

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07579845
Status	Recruiting
Phase	Not applicable
Study type	Interventional; na, single group, masking: none, other
Enrollment	60 (Estimated)
Sponsor	OvationLab (Network)
Conditions	Detoxification, Inflammation, Biological Aging
Interventions	Humic and Fulvic Acid Dietary Supplement (Dietary supplement)
Dates	start 2026-05-05, primary completion 2026-09-01 (estimated), completion 2026-09-01 (estimated), first posted 2026-05-12, last updated 2026-05-29
Locations	1 site in United States

-Summary

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Humic and Fulvic Acid Dietary Supplement	Experimental	Dietary Supplement: Humic and Fulvic Acid Dietary Supplement

Humic and Fulvic Acid Dietary Supplement (Dietary supplement): BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement

+Outcome measures

Primary outcomes

TruDiagnostic - Epigenetic Testing [Change in TruAge from baseline to 12 weeks]: TruAge Test

+Eligibility

Sex: All, ages: 40 Years to any, accepts healthy volunteers

Inclusion Criteria:

1. Adult females or males age ≥ 40 years
2. Ability to read and speak English

Exclusion Criteria:

1. Current use of a dietary supplement containing fulvic or humic acid
2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
3. Known allergies to any ingredients in the product
4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
6. Participants unable to provide consent

+Locations (1)

Facility	City	Country	Status
OvationLab	Richmond, Virginia	United States	Recruiting